SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for QUANTA INC (CIK 0001691430) — Feb 3, 2021

QUANTA INC (CIK 0001691430)
Date: Feb. 3, 2021 · CIK: 0001691430 · Accession: 0000000000-21-001426

AI Filing Summary & Sentiment

File numbers found in text: 333-252663

Date
February 3, 2021
Author
Not clearly detected
Form
UPLOAD
Company
QUANTA INC (CIK 0001691430)

Letter

United States securities and exchange commission logo February 3, 2021 Arthur Mikaelian Chief Executive Officer and Chief Financial Officer Quanta, Inc. 3606 W. Magnolia Blvd. Burbank, CA 91505 Re:Quanta, Inc. Registration Statement on Form S-1 Filed February 2, 2021 File No. 333-252663 Dear Mr. Mikaelian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact David Gessert at 202-551-2326 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
United States securities and exchange commission logo
February 3, 2021
Arthur Mikaelian
Chief Executive Officer and Chief Financial Officer
Quanta, Inc.
3606 W. Magnolia Blvd.
Burbank, CA 91505
Re:Quanta, Inc.
Registration Statement on Form S-1
Filed February 2, 2021
File No. 333-252663
Dear Mr. Mikaelian:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact David Gessert at 202-551-2326 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences